Physician profile
Robert C Rollings
NPI 1558351544
$1,533.18
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $499 · 2020: $62.91 · 2022: $44.86 · 2023: $357 · 2024: $569.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $926.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $925.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $269.64 | 2019-2024 | Lifevest |
| Novartis Pharmaceuticals Corporation | $156.91 | 2019-2024 | |
| Edwards Lifesciences Corporation | $142.25 | 2023-2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Pascal |
| Merck Sharp & Dohme LLC | $112.69 | 2023-2024 | Verquvo, Winrevair |
| Pfizer INC. | $111.43 | 2019-2024 | |
| Boston Scientific Corporation | $108.67 | 2022-2024 | Watchman Flx, Bodyguardian |
| Amgen INC. | $104.40 | 2019-2024 | Repatha |
| Janssen Pharmaceuticals, INC | $81.96 | 2019-2024 | Xarelto |
| Astellas Pharma US INC | $55.46 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $51.52 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $49.94 | 2019 | |
| Esperion Therapeutics, INC. | $48.50 | 2023-2024 | Nexletol |
| Abbott Laboratories | $44.18 | 2024 | Cardiomems, Jot Dx |
| Kowa Pharmaceuticals America, INC. | $27.76 | 2019 | |
| Amarin Pharma, INC. | $21.56 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $21.05 | 2023 | Injectafer |
| Scpharmaceuticals INC. | $19.15 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.80 | 2024 | Jardiance |
| Regeneron Healthcare Solutions, INC. | $16.53 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $16.11 | 2023 | Arcalyst |
| Lundbeck LLC | $14.71 | 2019 | |
| Ge Healthcare | $14.45 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $13.51 | 2023 | Opsumit, Uptravi |
| Bardy Diagnostics, INC. | $13.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Rollings listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.